Peter Quehenberger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2453242/publications.pdf

Version: 2024-02-01

57 papers	1,215 citations	430874 18 h-index	414414 32 g-index
60 all docs	60 docs citations	60 times ranked	1893 citing authors

#	Article	IF	Citations
1	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
2	Culprit site extracellular DNA and microvascular obstruction in ST-elevation myocardial infarction. Cardiovascular Research, 2022, 118, 2006-2017.	3.8	16
3	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clinical Gastroenterology and Hepatology, 2022, 20, 1362-1373.e6.	4.4	39
4	The von Willebrand factor A-1 domain binding aptamer BT200 elevates plasma levels of von Willebrand factor and factor VIII: a first-in-human trial. Haematologica, 2022, 107, 2121-2132.	3.5	16
5	Lupus anticoagulant test persistence over time and its associations with future thrombotic events. Blood Advances, 2022, , .	5.2	1
6	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. Journal of Hepatology, 2022, 76, 1090-1099.	3.7	26
7	Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy. Pharmaceutics, 2022, 14, 662.	4.5	3
8	Multicenter performance evaluation and reference range determination of a new oneâ€stage factor VIII assay. Journal of Clinical Laboratory Analysis, 2022, 36, e24294.	2.1	2
9	Assay validity of point-of-care platelet function tests in thrombocytopenic blood samples. Biochemia Medica, 2022, 32, 291-301.	2.7	2
10	The VWF binding aptamer rondoraptivon pegol increases platelet counts and VWF/FVIII in type 2B von Willebrand disease. Blood Advances, 2022, 6, 5467-5476.	5.2	6
11	Immature cell fractions after cessation of chronic P2Y₁₂-inhibition in patients with coronary artery diseases. Platelets, 2021, 32, 815-820.	2.3	1
12	Emicizumab for the treatment of acquired hemophilia A. Blood, 2021, 137, 410-419.	1.4	83
13	Limitations of a calibrated, quantitative APCâ€R assay under routine conditions. International Journal of Laboratory Hematology, 2021, 43, 318-323.	1.3	5
14	A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. EBioMedicine, 2021, 67, 103348.	6.1	34
15	Successful treatment of vaccineâ€induced prothrombotic immune thrombocytopenia (VIPIT). Journal of Thrombosis and Haemostasis, 2021, 19, 1819-1822.	3.8	91
16	Safety of direct oral anticoagulants in patients with advanced liver disease. Liver International, 2021, 41, 2159-2170.	3.9	36
17	Prevalence and Clinical Impact of Reduced Coagulation Factor XII Activity in Patients Receiving Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2021, 49, e1206-e1211.	0.9	10
18	Long-term follow-up after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia. Thrombosis Research, 2021, 207, 126-130.	1.7	15

#	Article	IF	Citations
19	Delayed Plasma Clot Lysis in Adult Patients with Primary Immune Thrombocytopenia (ITP). Blood, 2021, 138, 3162-3162.	1.4	1
20	Renal Function and Risk of Arterial Thrombotic Events in Patients Positive for Lupus Anticoagulant. Blood, 2021, 138, 290-290.	1.4	0
21	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. Journal of Personalized Medicine, 2021, 11, 1264.	2.5	10
22	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. Hepatology International, 2020, 14, 1083-1092.	4.2	9
23	Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. Clinical Chemistry, 2020, 66, 1405-1413.	3.2	122
24	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatology International, 2020, 14, 1093-1103.	4.2	12
25	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. Liver International, 2020, 40, 1415-1426.	3.9	21
26	Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in nonâ€severe haemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 1081-1086.	3.8	13
27	Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal Dâ€Dimer analysis: A prospective study. Journal of Thrombosis and Haemostasis, 2020, 18, 1348-1356.	3.8	34
28	Anticoagulation strategy in a patient on the HeartMate IIIÂ® left ventricular assist device with acquired von Willebrand syndrome and recurring gastrointestinal bleeding episodes: sometimes less is more. European Journal of Cardio-thoracic Surgery, 2019, 57, 796-798.	1.4	1
29	Interference in specialized coagulation assays affecting the protein C pathway: Effects of marked haemolysis, hyperbilirubinaemia and lipaemia on chromogenic and clotting tests on two coagulation platforms. International Journal of Laboratory Hematology, 2019, 41, 404-411.	1.3	5
30	Factor VIII Levels in Blood Group O and Non-O in Patients with Non-Severe Haemophilia a. Blood, 2019, 134, 1135-1135.	1.4	0
31	Correlation of Factor Levels with Bleeding Phenotype in Non-severe Hemophilia. , 2019, 39, .		0
32	Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clinical and Experimental Medicine, 2018, 18, 325-336.	3.6	21
33	Dynamic reference intervals for coagulation parameters from infancy to adolescence. Clinica Chimica Acta, 2018, 482, 124-135.	1.1	17
34	The Effect of 3.2% and 3.8% Sodium Citrate on Specialized Coagulation Tests. Archives of Pathology and Laboratory Medicine, 2018, 142, 992-997.	2.5	3
35	Evaluating the analytical performance of five new coagulation assays for the measurement of prothrombin time and activated thromboplastin time. International Journal of Laboratory Hematology, 2018, 40, 645-654.	1.3	13
36	Evaluating the analytical performance of four new coagulation assays for the measurement of fibrinogen, Dâ€dimer and thrombin time. International Journal of Laboratory Hematology, 2018, 40, 637-644.	1.3	8

#	Article	IF	Citations
37	Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases. Blood, 2018, 132, 2476-2476.	1.4	8
38	Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. Annals of Hematology, 2017, 96, 489-495.	1.8	21
39	Women with homozygous AT deficiency type II heparin-binding site (HBS) are at high risk of pregnancy loss and pregnancy complications. Annals of Hematology, 2017, 96, 1023-1031.	1.8	21
40	Homozygous antithrombin deficiency type II causing neonatal thrombosis. Thrombosis Research, 2017, 158, 134-137.	1.7	8
41	Evaluation of between-, within- and day-to-day variation of coagulation measured by rotational thrombelastometry (ROTEM). Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 651-657.	1.2	10
42	Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant. BMC Medicine, 2017, 15, 54.	5.5	20
43	Testing lupus anticoagulants in a real-life scenario - a retrospective cohort study. Biochemia Medica, 2017, 27, 030705.	2.7	2
44	Lupus-anticoagulant testing at NOAC trough levels. Thrombosis and Haemostasis, 2016, 116, 235-240.	3.4	47
45	FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors. Blood, 2016, 128, 293-296.	1.4	34
46	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Digestive and Liver Disease, 2016, 48, 1194-1199.	0.9	1
47	Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 249-255.	1.2	11
48	Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent. Thrombosis Research, 2016, 137, 196-201.	1.7	48
49	Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood, 2015, 125, 3477-3483.	1.4	63
50	A model comparing how rapidly transfusion of solvent detergent plasma restores clotting factors versus infusion of albumin-saline. Transfusion and Apheresis Science, 2015, 53, 360-367.	1.0	1
51	Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thrombosis Research, 2014, 134, 918-923.	1.7	66
52	Acquired Von Willebrand Factor Deficiency Caused By Left Ventricular Assist Devices Is Adamts-13 Dependent. Blood, 2013, 122, 3602-3602.	1.4	0
53	Monitoring of ADAMTS13 in Patients with Thrombotic Thrombocytopenic Purpura: Prediction of Response to Therapy, Risk of Relapse, and Long- Term Outcome.. Blood, 2008, 112, 2291-2291.	1.4	2
54	Predictive Value of D-Dimer Levels for Venous Thromboembolism in Cancer Patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 2008, 112, 3824-3824.	1.4	2

#	Article	IF	Citations
55	Clinical evaluation of a new functional test for detection of activated protein C resistance (PefakitÂ®) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	16
56	The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thrombosis Research, 2007, 120, 295-302.	1.7	14
57	High Concentrations of Soluble P-Selectin Are Associated with Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant. Clinical Chemistry, 2007, 53, 1235-1243.	3.2	110